120,832 The Chemours Company $CC Shares Acquired by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. lifted its holdings in shares of The Chemours Company (NYSE:CC) by 150.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 201,082 shares of the specialty chemicals company’s stock after acquiring an additional 120,832 shares during the period. Pekin Hardy Strauss Inc. owned 0.13% of Chemours worth $2,729,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CC. Northwestern Mutual Wealth Management Co. acquired a new stake in Chemours during the 2nd quarter worth $34,000. Allworth Financial LP purchased a new position in Chemours during the 2nd quarter worth $51,000. State of Wyoming acquired a new position in Chemours in the second quarter valued at $67,000. Sterling Capital Management LLC increased its stake in Chemours by 839.3% in the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after purchasing an additional 4,532 shares during the period. Finally, Nykredit A S acquired a new position in Chemours in the second quarter valued at $99,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Trading Down 7.4%

NYSE CC opened at $12.77 on Friday. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. The Chemours Company has a 52-week low of $10.44 and a 52-week high of $28.67. The firm has a 50-day moving average price of $14.02 and a 200 day moving average price of $18.23. The company has a quick ratio of 0.88, a current ratio of 1.81 and a debt-to-equity ratio of 24.25.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the prior year, the firm posted $0.40 EPS. Chemours’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities research analysts expect that The Chemours Company will post 0.81 EPS for the current year.

Chemours Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be paid a $0.0875 dividend. The ex-dividend date is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. Chemours’s payout ratio is -34.31%.

Insider Buying and Selling

In other Chemours news, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction on Wednesday, August 12th. The stock was bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares in the company, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Denise Dignam bought 3,378 shares of Chemours stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, with a total value of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their position. The SEC filing for this purchase provides additional information. 0.85% of the stock is owned by insiders.

Key Headlines Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Morgan Stanley set a $18.00 target price on shares of Chemours in a research note on Monday, August 10th. Royal Bank Of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a research report on Tuesday, October 13th. Truist Financial reduced their price objective on Chemours from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemours in a research note on Tuesday. Finally, BMO Capital Markets decreased their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.45.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.